Eriko Yasuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eriko Yasuda has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Shunji Tomatsu
Department of Pediatrics, Gifu University School of Medicine, Gifu, Japan
6 shared publications - Tadao Orii
Department of Human Welfare, Chubu Gakuin University, Faculty of Human Welfare, Kurachi, Seki, Japan
6 shared publications - Francyne Kubaski
Greenwood Genetic Center, Greenwood, SC, USA
5 shared publications - Robert W. Mason
Laboratory of Enzymology, Department of Research, Alfred I. duPont Hospital for Children, P.O. Box 269, Wilmington, DE 19899, U.S.A.
5 shared publications - Tsutomu Shimada
Department of Hospital Pharmacy, University Hospital, Kanazawa University
4 shared publications Yasuyuki Suzuki
4 shared publications
Latest Publications
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S116
Novel heparan sulfate assay by using automated high throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S116
Novel heparan sulfate assay by using automated high throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S116
Long-term follow up of post-hematopoietic stem cell transplantation for Hurler syndrome: Clinical biochemical and pathological improvements
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S116
Long-term follow up of post-hematopoietic stem cell transplantation for Hurler syndrome: Clinical biochemical and pathological improvements
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S115
Activity of daily life in patients with Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S115
Activity of daily life in patients with Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S67
Noninvasive pulmonary function test on Morquio syndrome type A patients
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S67
Noninvasive pulmonary function test on Morquio syndrome type A patients
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S66-S67
Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis IVA
- 1 February 2015
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 114 (2) , S66-S67
Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis IVA
- Open Access
- 11 August 2014
- Published by MDPI AG in Metabolites
- Vol. 4 (3) , 655-679
Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of the lysosomal enzymes essential for catabolism of glycosaminoglycans (GAGs). Accumulation of undegraded GAGs results in dysfunction of multiple organs, resulting in distinct clinical manifestations. A range of methods have been developed to measure specific GAGs in various human samples to investigate diagnosis, prognosis, pathogenesis, GAG interaction with other molecules, and monitoring therapeutic efficacy. We established ELISA, liquid chromatography tandem mass spectrometry (LC-MS/MS), and an automated high-throughput mass spectrometry (HT-MS/MS) system (RapidFire) to identify epitopes (ELISA) or disaccharides (MS/MS) derived from different GAGs (dermatan sulfate, heparan sulfate, keratan sulfate, and/or chondroitin sulfate). These methods have a high sensitivity and specificity in GAG analysis, applicable to the analysis of blood, urine, tissues, and cells. ELISA is feasible, sensitive, and reproducible with the standard equipment. HT-MS/MS yields higher throughput than conventional LC-MS/MS-based methods while the HT-MS/MS system does not have a chromatographic step and cannot distinguish GAGs with identical molecular weights, leading to a limitation of measurements for some specific GAGs. Here we review the advantages and disadvantages of these methods for measuring GAG levels in biological specimens. We also describe an unexpected secondary elevation of keratan sulfate in patients with MPS that is an indirect consequence of disruption of catabolism of other GAGs.
- 11 August 2014
- Published by MDPI AG in Metabolites
- Vol. 4 (3) , 655-679
Open AccessEstablishment of Glycosaminoglycan Assays for Mucopolysaccharidoses
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of the lysosomal enzymes essential for catabolism of glycosaminoglycans (GAGs). Accumulation of undegraded GAGs results in dysfunction of multiple organs, resulting in distinct clinical manifestations. A range of methods have been developed to measure specific GAGs in various human samples to investigate diagnosis, prognosis, pathogenesis, GAG interaction with other molecules, and monitoring therapeutic efficacy. We established ELISA, liquid chromatography tandem mass spectrometry (LC-MS/MS), and an automated high-throughput mass spectrometry (HT-MS/MS) system (RapidFire) to identify epitopes (ELISA) or disaccharides (MS/MS) derived from different GAGs (dermatan sulfate, heparan sulfate, keratan sulfate, and/or chondroitin sulfate). These methods have a high sensitivity and specificity in GAG analysis, applicable to the analysis of blood, urine, tissues, and cells. ELISA is feasible, sensitive, and reproducible with the standard equipment. HT-MS/MS yields higher throughput than conventional LC-MS/MS-based methods while the HT-MS/MS system does not have a chromatographic step and cannot distinguish GAGs with identical molecular weights, leading to a limitation of measurements for some specific GAGs. Here we review the advantages and disadvantages of these methods for measuring GAG levels in biological specimens. We also describe an unexpected secondary elevation of keratan sulfate in patients with MPS that is an indirect consequence of disruption of catabolism of other GAGs.
- 1 February 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (2) , S91-S92
Establishment of Morquio tissue repository bank
- 1 February 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (2) , S91-S92
Establishment of Morquio tissue repository bank